ArticleMacromolecular bioscience2026
Serum-Integrated Dopamine-Hyaluronic Acid Hydrogels for Injectable Soft-Tissue Microenvironment Modulation.
Article in Macromolecular bioscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyaluronic acid (HA) hydrogels are widely used as injectable fillers for soft-tissue augmentation; however, most currently available formulations primarily provide structural support with limited biological activity. This work establishes design principles for integrating autologous biological components into catechol-based HA (DaHA) hydrogels and underscores the potential of DaHA-serum systems as bioactive injectable platforms. In this study, human whole serum was incorporated into DaHA hydrogels bsy replacing the aqueous phase during hydrogel preparation (0%-10% v/v). Serum incorporation accelerated gelation and altered the viscoelastic behavior of the resulting hydrogels while maintaining injectability through small-gauge needles. Rheological characterization demonstrated stable gel formation, shear recovery, and favorable mechanical properties, whereas moderate serum incorporation (under 10% v/v) preserved swelling behavior and structural stability. Sustained release of serum-derived proteins was observed for at least 8 days, indicating prolonged biochemical availability within the hydrogel matrix. In vitro studies using L929 fibroblasts demonstrated suitable cytocompatibility and enhanced cell survival under serum-free culture conditions. Subcutaneous implantation further confirmed good in vivo tolerance, minimal inflammatory response, and gradual tissue integration. These findings demonstrate that controlled incorporation of human serum provides a practical strategy for engineering bioactive catechol-based hydrogels while preserving the physicochemical properties required for injectable soft-tissue filler applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.